Genetic and clinical evidence supports HLA-DR+ CD8+ T cells as a favorable immune biomarker in acute myeloid leukemia
Abstract
Immune dysregulation is central to acute myeloid leukemia (AML), but the contribution of specific immune subsets remains uncertain. We combined Mendelian randomization (MR), clinical flow cytometry, and transcriptomic profiling to investigate HLA-DR+ CD8+ T cells in AML. Two-sample MR using 731 immunophenotypes and AML data from UK Biobank and FinnGen identified four HLA-DR-related T-cell traits associated with lower AML susceptibility. In 85 non-APL patients, HLA-DR+ CD8+ T-cell proportions increased after complete remission, while among 46 newly diagnosed patients, a lower baseline HLA-DR+ CD8+ T-cell proportion was associated with poorer overall survival after adjustment for age and ELN risk category (HR 3.32, 95% CI 1.09-10.16, P = 0.035). A nomogram incorporating clinical and immune variables stratified patient risk. Transcriptomic analysis linked lower HLA-DR+ CD8+ T-cell levels to ribosomal and extracellular matrix pathways. These findings support HLA-DR+ CD8+ T cells as a favorable immune biomarker and clinically relevant immune correlate in AML.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677 · see citing works
Emdin, C. A., Khera, A. V., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2017.17219 · Cited by 3,637 · see citing works
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., Dinardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,430 · see citing works
Foreman, K. J., Marquez, N., Dolgert, A. J., Fukutaki, K. G., Fullman, N., McGaughey, M., Pletcher, M. A., Smith, A. E., Tang, K., Yuan, C.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31694-5 · Cited by 3,048 · see citing works
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400 · see citing works
Short, N. J., Rytting, M., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 815 · see citing works
An update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2015) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 556 · see citing works
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 544 · see citing works
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D. J., Ivey, A., & Huntly, B. J. P. (2015) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 451 · see citing works
Recent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 288 · see citing works
Regulation of hematopoietic and leukemic stem cells by the immune system
Riether, C., Schürch, C. M., & Ochsenbein, A. F. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.89 · Cited by 246 · see citing works
Walker, V. M., Smith, G. D., Davies, N. M., & Martin, R. M. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx207 · Cited by 220 · see citing works
Knaus, H. A., Berglund, S., Hackl, H., Blackford, A. L., Zeidner, J. F., Montiel-Esparza, R., Mukhopadhyay, R., Vanura, K., Blazar, B. R., Karp, J. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120974 · Cited by 216 · see citing works
Vadakekolathu, J. N., Minden, M. D., Hood, T., Church, S., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E., Patel, T., Ibrahimova, N., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz0463 · Cited by 215 · see citing works
NK Cell-Based Immunotherapy in Cancer Metastasis
Lorenzo‐Herrero, S., López‐Soto, A., Sordo‐Bahamonde, C., González, A. P., Vitale, M., & Gonzalez, S. R. (2018) · Cancers · doi:10.3390/cancers11010029 · Cited by 113 · see citing works
Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 97 · see citing works
Rutella, S., Vadakekolathu, J. N., Mazziotta, F., Reeder, S., Yau, T. O., Mukhopadhyay, R., Dickins, B., Altmann, H., Krämer, M., Knaus, H. A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159579 · Cited by 96 · see citing works
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
Mazziotta, F., Biavati, L., Rimando, J. C., Rutella, S., Borcherding, N. C., Parbhoo, S., Mukhopadhyay, R., Chowdhury, S., Knaus, H. A., Valent, P., et al. (2024) · Blood · doi:10.1182/blood.2023021680 · Cited by 40 · see citing works
Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia
Ismail, M. M., & Abdulateef, N. A. B. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2153-5 · Cited by 38 · see citing works
Fang, J., Zhang, R., Lin, X., Xu, Y. X., Huang, K., & Saw, P. E. (2023) · Hematology · doi:10.1080/16078454.2023.2219554 · Cited by 9 · see citing works
Su, P., Jian, A., Yu, L., Lei, H., Huang, L., Mao, X., & Sun, P. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s388993 · Cited by 7 · see citing works
Hu, L., Luo, Q., Liao, Y. L., Zhai, Z., Ding, Y., & Yan, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1659811 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Still being checked.
- Authors
- Chen, G., Xu, J., He, X., Yan, Y., Hu, L., & Li, Z.
- Affiliations
- Second Affiliated Hospital of Nanchang University (CN)
- Corresponding author
- Hu, Linhui
- Li, Zhenjiang
- ORCID
- Xu, Jing
- Venue
- Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2026-12
- Volume
- 288
- Pages
- 110785
- ISSN
- 1521-6616 (ISSN-L)
- OpenAlex
- W7222801336
- Cited by
- 0
- References
- 23
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Jiangxi Provincial Natural Science Foundation
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- HLA-DR, CD8+ T cells, acute myeloid leukemia, immunological markers, prognostic factors, T cell activation, leukemia immunology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
